INVESTORS

Driven by patient need, we have the potential to transform the treatment of NASH

NASDAQ: MDGL

 

INVESTORS

Driven by patient need, we have the potential to transform the treatment of NASH

NASDAQ: MDGL

Potential first-to-market therapy for patients with non-alcoholic steatohepatitis (NASH)

At Madrigal, we are developing a potential first-to-market therapy for patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Our most advanced clinical candidate, resmetirom, is designed specifically to treat the underlying causes of the disease. Madrigal has an experienced management team and is poised to become the leader in the treatment of NASH with fibrosis.